Generalized anxiety disorder
Methodology & AI Transparency ⓘ
Generalized anxiety disorder Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Generalized anxiety disorder—coded clinically as F41.1 across Anxiety & PTSD guidelines—combines non-habit-forming pharmacotherapy planning [Generalized anxiety disorder F41.1] with structured follow-up of Resting Heart Rate in Generalized anxiety disorder (F41.1: Variability (HRV)) (Stable upward personal trend (F41.1)).
- 2 Real-world patient consensus: Clinical coding for Generalized anxiety disorder uses ICD-10 F41.1 across Anxiety & PTSD specialty care.
- 3 Typical cash cost range: Differential triage of Generalized anxiety disorder (F41.1) utilizes non-habit-forming pharmacotherapy planning [Generalized anxiety disorder F41.1].
- 4 Top reported side effects / signs: Objective lab/clinical target for Generalized anxiety disorder: GAD-7 Anxiety Severity in Generalized anxiety disorder (F41.1: Score) (< 4 (minimal anxiety) (F41.1)) and Resting Heart Rate in Generalized anxiety disorder (F41.1: Variability (HRV)).
Ask our AI Specialists anything about Generalized anxiety disorder
What Is Generalized anxiety disorder?
Generalized anxiety disorder—coded clinically as F41.1 across Anxiety & PTSD guidelines—combines non-habit-forming pharmacotherapy planning [Generalized anxiety disorder F41.1] with structured follow-up of Resting Heart Rate in Generalized anxiety disorder (F41.1: Variability (HRV)) (Stable upward personal trend (F41.1)).
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Generalized anxiety disorder (ICD-10 F41.1) is driven by conditioned fear-extinction deficits [Generalized anxiety disorder F41.1]; specialists in Anxiety, OCD & Trauma Disorders monitor Resting Heart Rate in Generalized anxiety disorder (F41.1: Variability (HRV)) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Generalized anxiety disorder (F41.1): avoidance of triggers, in Generalized anxiety disorder (F41.1: intrusive trauma memories,)
- • Secondary Generalized anxiety disorder clinical sign: excessive, hard-to-control anticipatory in Generalized anxiety disorder (F41.1: worry or intrusive)
- • Symptom flares in Generalized anxiety disorder correlating with GAD-7 Anxiety Severity in Generalized anxiety disorder (F41.1: Score) deviation outside < 4 (minimal anxiety) (F41.1)
- • Functional anxiety & ptsd impact requiring non-habit-forming pharmacotherapy planning [Generalized anxiety disorder F41.1] evaluation (F41.1)
Generalized anxiety disorder Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F41.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Anxiety, OCD & Trauma Disorders | NLM Clinical Tables |
| Diagnostic / Lab Marker: GAD-7 Anxiety Severity in Generalized anxiety disorder (F41.1: Score) | < 4 (minimal anxiety) (F41.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Resting Heart Rate in Generalized anxiety disorder (F41.1: Variability (HRV)) | Stable upward personal trend (F41.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & Ferritin in Generalized anxiety disorder (F41.1: Rule-Out) | TSH 0.8–2.5 mIU/L; Ferritin > 50 ng/mL (F41.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Generalized anxiety disorder
Treatment selection for Generalized anxiety disorder depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Generalized anxiety disorder)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Sertraline treatment for generalized anxiety: a randomized, gold-standard blind,: What a 326-Participant Study Found Despite the relatively small between-group differences, study findings suggest a role for sertraline in the acute treatment of GAD. The Journal of clinical psychiatry • 2006-06-15 • Randomized Controlled Trial | N = 326 | 93/100 | PMID 16848646 ↗ |
| New Insights on Benefits and safety of etifoxine versus alprazolam in generalized anxiety with: What a 260-Participant Study Found Treatment-emergent AEs were mild and observed in 10% and 7.7% of patients in the Etifoxine and Alprazolam groups, respectively. Journal of anxiety disorders • 2026-04-15 • Phase III Randomized Trial | N = 260 | 93/100 | PMID 41763071 ↗ |
| What the Latest Evidence Really Says About Comparative real-world benefits and safety of Benzodiazepines in the Treatment of BZDs are overall efficacious for the treatment of GAD and have a favorable safety profile. Psychotherapy and psychosomatics • 2025-01-15 • Meta-Analysis | Multi-cohort | 92/100 | PMID 40544830 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy of sertraline in a 12-week trial for generalized Sertraline appears to be efficacious and well tolerated in the treatment of generalized anxiety. The American journal of psychiatry • 2004-09-15 • Randomized Controlled Trial | N = 188 | 88/100 | PMID 15337655 ↗ |
| Can This Approach Help? Inside the Latest Research on Sertraline in generalized anxiety: efficacy in treating the psychic and somatic Sertraline treatment demonstrated efficacy for both the psychic and somatic anxiety symptoms of GAD. Acta psychiatrica Scandinavica • 2005-06-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 15877709 ↗ |
Generalized anxiety disorder Patient Community & “People Like Me” Threads
Filter Generalized anxiety disorder community threads and patient logs by age, biological sex, dosage, and treatment duration.